Clinical trials: glp1 Agonist
Healthy, Hepatic Insufficiency
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05882032
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity, Aging
Semaglutide Use in Elderly Obese Patients
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly…
- Trial name
- NCT05302596
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Alcohol Use Disorder
The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers
A double-blind, randomized, placebo-controlled, crossover design trial was used to test the effect of exenatide on alcohol self-administration and craving following a priming dose of alcohol.
- Trial name
- NCT03645408
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Diabetes Mellitus, Type 2
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose.
- Trial name
- NCT03331289
- Testing
- Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus, Bone Remodeling
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
The purpose of this study is to determine changes in bone turnover markers and calcitonin following the initiation of exenatide compared to placebo in postmenopausal women wtih type 2 diabetes.
- Trial name
- CMBD (NCT01381926)
- Testing
- exenatide, Saline
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore